Schering-Plough R&D Pipeline Sticks To Traditional Strengths
Executive Summary
Schering-Plough's R&D efforts build on the company's existing therapeutic areas, according to the drug maker's R&D update Nov. 1
You may also be interested in...
Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.
Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended
Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.
Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20